Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.81 |
| ▸ | NQO2 | P16083 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21322208 | 1.00 | MET (0.81) | METNQO2CXCR1CREBBPVNN1 | |
| SCHEMBL21264839 | 0.92 | MET (0.68) | METNQO2KDM1A | |
| SCHEMBL21264513 | 0.89 | MET (1.00) | METNQO2CXCR1VNN1AVPR1B | |
| SCHEMBL21264643 | 0.89 | MET (1.00) | METNQO2CXCR1VNN1AVPR1B | |
| SCHEMBL21264509 | 0.84 | MET (0.68) | METNQO2CXCR1VNN1 | |
| SCHEMBL23344105 | 0.82 | MET (0.72) | METNQO2CXCR1CREBBPVNN1 | |
| SCHEMBL23344092 | 0.82 | MET (0.72) | METNQO2CXCR1CREBBPVNN1 | |
| SCHEMBL23344103 | 0.82 | MET (0.72) | METNQO2CXCR1CREBBPVNN1 | |
| SCHEMBL21264737 | 0.81 | MET (0.85) | METNQO2KDM1A | |
| SCHEMBL21322011 | 0.81 | MET (0.56) | METNQO2CXCR1AVPR1BCTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501443-B2 | Pyridone compound as c-met inhibitor | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | US | disclosed |
| EP-3533787-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | Fujian Cosunter Pharmaceutical Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248763-A1 | PYRIDONE COMPOUND AS C-MET INHIBITOR | MET, PDXK, RET | MET 1/4885NQO2 2416/4885CXCR1 2278/4885 |
| US-10501443-B2 | Pyridone compound as c-met inhibitor | MET, PDXK, RET | MET 1/4885NQO2 2416/4885CXCR1 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.